Digital healthcare startup Ransik announced that it has completed the regulatory approval procedures for the domestic launch of “GS1,” a product from global continuous glucose monitoring (CGM) company SIBIONICS. Based on this approval, Ransik plans to begin full-scale preparations for launch, including building domestic distribution and customer support systems.

SIBIONICS is one of the major companies in the global CGM market, and GS1 has obtained the European CE mark, securing product accuracy and reliability. The company is also regarded as having grown rapidly in more than 100 markets worldwide, backed by a stable customer support system and competitive, reasonable pricing.

Ransik’s AI-based glucose management platform “Glucofit” is a glucose management service designed to allow users to view blood glucose data on a single platform even when using multiple types of CGMs, and to analyze it together with lifelog data such as diet, activity, and sleep. Ransik has been expanding its foundation as a glucose management platform by integrating a wide range of major CGM models already distributed in Korea.

With the completion of GS1 approval, Ransik will expand its business scope from platform-centered services to a model that also connects domestic distribution and service operations for global CGM products. Through this, domestic users are expected to be able to use the Glucofit service with a wider range of CGM options.

Yang Hyuk-yong, CEO of Ransik, stated, “Glucofit has grown into a platform that integrates data from various CGMs and analyzes it together with lifelogs,” adding, “With the completion of GS1 approval and collaboration with SIBIONICS, we will expand linkage with global products and further advance service and data-based functions that can be utilized in hospital and corporate environments.”

HU ZHI-GANG, Executive Vice President of SIBIONICS, said, “SIBIONICS is an innovation company dedicated to the research, development, and commercialization of advanced active implantable medical devices and medical artificial intelligence,” and added, “To address the global challenge of chronic diseases, we have continuously advanced core medical technologies and developed leading healthcare solutions.”

He continued, “Our commitment is to make quality medical care accessible to everyone at a reasonable cost and to deliver greater value to people around the world,” adding, “We are confident that combining the expertise of the Ransik team with the excellence of the Glucofit platform will provide users in the Korean market with a significantly enhanced experience.”

Meanwhile, Ransik is continuously expanding collaboration opportunities with medical and healthcare companies based on a platform strategy that integrates and utilizes diverse lifelog health data centered on glucose data. Going forward, Ransik plans to strengthen a data-driven healthcare ecosystem around Glucofit and actively pursue domestic and international partnerships.

Popular News